Abstract
A standard treatment option for patients with locally advanced thoracic esophageal squamous cell carcinoma (TESCC) is trimodality therapy, often consisting of neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery (1-4). However, transhiatal esophagectomy poses significant risks, including tracheal and pulmonary injury, anastomotic leak, vagus nerve injury, infection, and death. Therefore, two randomized trials have addressed this concern by comparing definitive CCRT (dCCRT) alone versus neoadjuvant CCRT (nCCRT) plus surgery in esophageal cancer (5,6). Both trials found no difference in overall survival (OS), but fewer local recurrences were observed in the nCCRT plus surgery groups. Major limitations of these trials included salvage therapy potentially confounding OS, the usage of induction chemotherapy (which is a widely utilized treatment strategy), patient selection based on induction chemotherapy response (6), and diminished applicability to current practice utilizing more advanced radiation techniques like intensity-modulated radiation therapy (IMRT). Consequently, recent high volume data addressing the therapeutic benefits of dCCRT versus nCCRT followed by surgery are lacking, and such data are needed to help inform the optimal management approach for TESCC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
